Notice: This company has been marked as potentially delisted and may not be actively trading. Interpace Biosciences (IDXG) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsHeadlinesTrends IDXG vs. NEO, VCYT, LH, DGX, DVA, CHE, CRVL, RCM, AMED, and MDShould you be buying Interpace Biosciences stock or one of its competitors? The main competitors of Interpace Biosciences include NeoGenomics (NEO), Veracyte (VCYT), Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Chemed (CHE), CorVel (CRVL), R1 RCM (RCM), Amedisys (AMED), and Pediatrix Medical Group (MD). Interpace Biosciences vs. NeoGenomics Veracyte Laboratory Co. of America Quest Diagnostics DaVita Chemed CorVel R1 RCM Amedisys Pediatrix Medical Group NeoGenomics (NASDAQ:NEO) and Interpace Biosciences (NASDAQ:IDXG) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, community ranking, media sentiment and valuation. Does the MarketBeat Community believe in NEO or IDXG? NeoGenomics received 183 more outperform votes than Interpace Biosciences when rated by MarketBeat users. However, 72.83% of users gave Interpace Biosciences an outperform vote while only 70.90% of users gave NeoGenomics an outperform vote. CompanyUnderperformOutperformNeoGenomicsOutperform Votes50270.90% Underperform Votes20629.10% Interpace BiosciencesOutperform Votes31972.83% Underperform Votes11927.17% Which has more volatility and risk, NEO or IDXG? NeoGenomics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Interpace Biosciences has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Is NEO or IDXG more profitable? Interpace Biosciences has a net margin of 10.39% compared to NeoGenomics' net margin of -12.07%. NeoGenomics' return on equity of -2.11% beat Interpace Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets NeoGenomics-12.07% -2.11% -1.18% Interpace Biosciences 10.39%-8.09%37.14% Do analysts prefer NEO or IDXG? NeoGenomics currently has a consensus target price of $20.25, suggesting a potential upside of 22.73%. Given NeoGenomics' stronger consensus rating and higher probable upside, equities analysts plainly believe NeoGenomics is more favorable than Interpace Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeoGenomics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Interpace Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation & earnings, NEO or IDXG? Interpace Biosciences has lower revenue, but higher earnings than NeoGenomics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoGenomics$591.64M3.58-$87.97M-$0.61-27.05Interpace Biosciences$40.21M0.36$800KN/AN/A Do institutionals and insiders hold more shares of NEO or IDXG? 98.5% of NeoGenomics shares are held by institutional investors. Comparatively, 5.7% of Interpace Biosciences shares are held by institutional investors. 1.3% of NeoGenomics shares are held by company insiders. Comparatively, 5.5% of Interpace Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer NEO or IDXG? In the previous week, NeoGenomics had 1 more articles in the media than Interpace Biosciences. MarketBeat recorded 4 mentions for NeoGenomics and 3 mentions for Interpace Biosciences. NeoGenomics' average media sentiment score of 0.53 beat Interpace Biosciences' score of 0.00 indicating that NeoGenomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Interpace Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryNeoGenomics beats Interpace Biosciences on 11 of the 16 factors compared between the two stocks. Ad Porter & CompanyFinancial Prophecy The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Get Interpace Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDXG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IDXG vs. The Competition Export to ExcelMetricInterpace BiosciencesSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.43M$4.60B$5.19B$8.93BDividend YieldN/A39.52%4.98%4.03%P/E RatioN/A25.03135.1217.46Price / Sales0.3661.421,273.5992.00Price / Cash4.7352.4438.8936.42Price / Book-0.255.596.325.94Net Income$800,000.00$13.58M$118.33M$224.98M Interpace Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IDXGInterpace BiosciencesN/A$3.28+9.7%N/A+177.4%$14.43M$40.21M0.00152News CoverageGap UpNEONeoGenomics2.4005 of 5 stars$16.34-0.1%N/A+2.2%$2.10B$644.12M-26.792,100VCYTVeracyte4.2023 of 5 stars$38.26-1.6%N/A+72.2%$2.94B$361.05M-255.07790Gap UpLHLaboratory Co. of America4.8151 of 5 stars$244.12+0.1%N/A+20.5%$20.42B$12.71B47.2267,000Insider SellingPositive NewsDGXQuest Diagnostics4.9004 of 5 stars$161.49+0.8%N/A+21.3%$18.02B$9.25B21.7148,000Dividend AnnouncementDVADaVita4.5145 of 5 stars$154.97+0.3%N/A+77.9%$12.71B$12.67B16.7270,000Positive NewsCHEChemed4.9221 of 5 stars$560.73-0.2%N/A-3.0%$8.44B$2.26B28.3315,087Dividend AnnouncementShort Interest ↑Positive NewsCRVLCorVel1.4274 of 5 stars$362.140.0%N/A+76.1%$6.20B$845.64M76.894,870Positive NewsRCMR1 RCM3.1627 of 5 stars$14.28-0.1%N/A+43.6%$6.03B$2.25B-95.1930,000AMEDAmedisys4.0234 of 5 stars$91.20-1.6%N/A-3.3%$2.99B$2.24B36.1919,000Short Interest ↑Analyst RevisionNews CoverageHigh Trading VolumeMDPediatrix Medical Group2.8772 of 5 stars$15.65-1.9%N/A+66.1%$1.34B$2.01B-5.115,170Analyst UpgradeInsider Selling Related Companies and Tools Related Companies NeoGenomics Competitors Veracyte Competitors Laboratory Co. of America Competitors Quest Diagnostics Competitors DaVita Competitors Chemed Competitors CorVel Competitors R1 RCM Competitors Amedisys Competitors Pediatrix Medical Group Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IDXG) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Interpace Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Interpace Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IDXG Stock Alerts